Olema Pharmaceuticals Inc. (OLMA) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
FRED Regime × Technicals: 4% of 52W Range • RSI-14 at 39.9 (NEUTRAL RANGE)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While OLMA currently carries a cautious 33/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.84) and Max Pain ($7.70) forces dealer call-delta covering toward $38.07.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Olema Pharmaceuticals Inc. (OLMA) dropped -2.14% to $7.33, trading at 4% of its 52-week range ($6.24 – $36.26). Stretched risk/reward at current multiples (-33% return on capital) under elevated 10-year interest-rate pressure.
AstraZeneca, Roche, Puma Biotechnology and Olema Oncology offer breast cancer treatment opportunities, with drug sales growth, pipeline advances and clinical milestones shaping prospects.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on OLMA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for OLMA. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Olema Pharmaceuticals Inc. (OLMA) ranks #865 by composite RQD confidence (33/100, grade E) and #414 by equity capitalization ($641.4M). Within this direct 5-issuer industry benchmark cohort, OLMA leads on earnings valuation at N/A trailing P/E, while LXRX leads on capital efficiency and profitability with -31.5% ROIC and 96.0% gross margin. BCAX currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with OLMA at 33/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| OLMA
ACTIVE
Olema Pharmaceuticals Inc. | E | 33/100 | — | — | -32.8% | -2.14% | $641.4M | Benchmark Subject |
| BCAX Bicara Therapeutics Inc. | D | 45/100 | — | — | -35.0% | -0.31% | $643.9M | /bcax-vs-olma → |
| ABUS Arbutus Biopharma Corporation | E | 22/100 | — | — | -35.0% | -0.93% | $656.0M | /abus-vs-olma → |
| LXRX Lexicon Pharmaceuticals Inc. | D- | 39/100 | — | 96.0% | -31.5% | -0.34% | $658.5M | /lxrx-vs-olma → |
| IMMX Immix Biopharma Inc. | E | 33/100 | — | — | -35.0% | -1.78% | $661.6M | /immx-vs-olma → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Olema Pharmaceuticals Inc. (OLMA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$162.5M, operating cash flow of -$146.7M, and free cash flow of -$146.7M (-40.4% YoY). On the balance sheet, OLMA closed FY2025 with $533.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$162.5M | -$146.7M | -$146.7M | $533.4M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$129.5M | -$104.4M | -$104.5M | $451.0M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$96.7M | -$83.7M | -$83.7M | — | — |
As of 2026-11-01, Olema Pharmaceuticals Inc. (NASDAQ: OLMA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $7.33 (-2.14% 1D, market cap $641.4M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, OLMA ranks #865 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OLMA carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -32.8%. By comparison, BCAX (Bicara Therapeutics Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $643.9M) and ABUS (Arbutus Biopharma Corporation) posts a E grade (22/100 RQD, P/E N/A, ROIC -35.0%, cap $656.0M). Among the 5-stock peer group, OLMA leads on earnings multiple (N/A) while LXRX leads on capital efficiency (-31.5% ROIC).
Per OLMA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001750284), Olema Pharmaceuticals Inc. generated $0 in revenue, -$162.5M in net income, and -$146.7M in free cash flow against $533.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
OLMA last traded at $7.33 (-2.14% on volume of 1,153,507 shares), positioning the stock -17.08% below its 50-day simple moving average ($8.84) and -47.75% below its 200-day simple moving average ($14.03). Across its 52-week range of $6.24 to $36.26, OLMA sits at the 3.6% percentile with a 14-day RSI of 39.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($6.41 to $8.25).
Why OLMA Stock dropped -2.14% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-33% return on capital) under elevated 10-year interest-rate pressure.